Paschalis Evangelidis: A New Way to Treat iTTP by Targeting the Autoimmune Process
Paschalis Evangelidis, Former Teaching Assistant at Aristotle University of Thessaloniki (AUTH) shared a post on LinkedInย about a recent article he and his colleagues co-authored, adding:
”Excited to share our insightful commentary on immune-mediated thrombotic thrombocytopenic purpura (iTTP):
This piece highlights a promising shift in how we think about iTTP – not just managing acute episodes, but targeting the underlying autoimmune process.
A novel approach using red blood cells to deliver ADAMTS13 antigens in an ‘immune-silent’ way could help induce immune tolerance and reduce relapses.
While still early, this strategy opens the door to more precise, long-term solutions beyond conventional immunosuppression.
A small but meaningful step toward solving another piece of the TTP puzzle.”
Title: Solving another piece of the thrombotic thrombocytopenic purpura puzzle?
Authors: Paschalis Evangelidis, Eleni Gavriilaki
Stay updated on all scientific advances withย Hemostasis Today.
-
Apr 17, 2026, 14:27Happy World Hemophilia Day – WFH
-
Apr 17, 2026, 13:59Donna Morelli: Personalized Cardiovascular Risk Assessment Through AI-Based Multiomics Modeling
-
Apr 17, 2026, 13:27Abdalraheim Mustafa: Comparative Analysis of Thrombophilia and Thrombocytosis in Clinical Practice
-
Apr 17, 2026, 13:25Emphasizing The Importance Of Early Diagnosis For Improving Hemophilia Care In Armenia – Yeolyan Hematology and Oncology Center
-
Apr 17, 2026, 13:05Flora Peyvandi: Key Guidance from ISTH on Pediatric Antithrombotic Therapies
-
Apr 17, 2026, 12:44Marc Carrier: A Practical Approach to Recurrent Thrombosis in Cancer Patients
-
Apr 17, 2026, 12:15Zain Khalpey: The Hidden Impact of Sex Hormones on Thrombosis and Heart Health
-
Apr 17, 2026, 09:54Andrew Aswani: How NETs Contribute to Disease and Why They Matter
-
Apr 17, 2026, 09:49Jeevandeep Mishra: Thrombotic Complications and Risk in COVID-19